Positrigo raises CHF 7M to accelerate nuclear brain imaging device production

Positrigo’s new financing round will boost production and enhance its commercial rollout of its NeuroLF system in the US and Europe. The round is supported by major investors like HealthCap and Navivo, along with returning investors. The NeuroLF system aims to assist in diagnosing brain disorders, including Alzheimer’s disease, which currently affects over 55 million people globally, a figure projected to reach 150 million by 2050. Three experienced board members will also join the team to strengthen leadership.

Positrigo, a Swiss company focused on nuclear medical devices for brain imaging, has closed a new financing round of 7 million CHF. This oversubscribed round strengthens its shareholders with lead investor HealthCap and Navivo, alongside existing shareholders and family offices.

Max Odlander from HealthCap will join Positrigo’s board to provide support.

Positrigo won Venture Kick final stage in 2018, participated in Venture Leaders Life Sciences 2019,  Venture Leaders China in 2020, Venture Leaders Deeptech in 2021, and was ranked at the TOP 100 Swiss Startup Awards in 2022 and 2023.